WP
CNTX icon

Woodline Partners’s Context Therapeutics CNTX Stock Holding History

Woodline Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$655K Buy
+250,088
New +$584K ﹤0.01% 930
2025
Q3 		– Sell
-680,188
Closed -$446K – 908
2025
Q2 		$446K Sell
680,188
-681,000
-50% -$490K ﹤0.01% 862
2025
Q1 		$833K Sell
1,361,188
-162
-0% -$141 0.01% 783
2024
Q4 		$1.43M Buy
1,361,350
+668
+0% +$1.16K 0.01% 707
2024
Q3 		$2.67M Buy
+1,360,682
New +$3.02M 0.02% 446

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Woodline Partners's CNTX Position: Q1 2026 in Review

Woodline Partners opened a new position in Context Therapeutics (CNTX) in Q1 2026: 250,088 shares worth $655K. The stake represents ﹤0.01% of the portfolio and ranks #930 among its holdings. This is a return to the name: Woodline Partners previously reported a position in CNTX as recently as Q2 2025.

Woodline Partners first reported a position in CNTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.67M in Q3 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Woodline Partners held 250,088 shares of Context Therapeutics worth $655K as of Q1 2026.
  • Context Therapeutics was a new Woodline Partners position in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #930 holding.
  • Woodline Partners first reported a position in Context Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Woodline Partners's Context Therapeutics position peaked at $2.67M in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.